Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target

NCT07390539 is registered in ClinicalTrials.gov with Robbie Majzner as lead sponsor.

NCT NCT07390539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07390539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target
Lead sponsor
Robbie Majzner
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2026
Completion date
August 31, 2032
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor, brain tumor, brain tumor adult, brain tumor, pediatric, brain tumor, recurrent, central nervous system neoplasms, embryonal tumor with multilayered rosettes, ependymoma, leptomeningeal disease, medulloblastoma, medulloblastoma recurrent, medulloblastoma, adult, medulloblastoma, childhood, pineoblastoma